The expression of p73, p21 and MDM2 proteins in gliomas

Journal of Neuro-Oncology

Volumn 59, Issue 2, 2002, Pages 143-149

  Kamiya, Makoto ^a   Nakazato, Yoichi ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Glioma; Immunohistochemistry; MDM2; p21; p73

Indexed keywords

MONOCLONAL ANTIBODY KI 67; PROTEIN MDM2; PROTEIN P21; PROTEIN P73;

ARTICLE; ASTROCYTOMA; CANCER CLASSIFICATION; CANCER GRADING; CONTROLLED STUDY; CORRELATION ANALYSIS; EPENDYMOMA; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; OLIGODENDROGLIOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

BRAIN NEOPLASMS; DNA-BINDING PROTEINS; GENES, TUMOR SUPPRESSOR; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; PROTO-ONCOGENE PROTEINS P21(RAS); SUBCELLULAR FRACTIONS; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 0036714949     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1019633910603     Document Type: Article

References (37)

1. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers
2. p73 is a simian (correction of human) p53-related protein that can induce apoptosis
3. Mdm2 binds p73 alpha without targeting degradation
4. Inactivation of the p53-homologue p73 by the mdm2-oncoprotein
5. MDM2 suppresses p73 function without promoting p73 degradation
6. Loss of imprinting and elevated expression of wild-type p73 in human gastric adenocarcinoma
7. The expression of p73 is increased in lung cancer, independent of p53 gene alteration
8. Overexpression of the wild type p73 gene in breast cancer tissues and cell lines
9. Overexpression of the wild type p73 gene in human bladder cancer
10. Molecular alterations of p73 in human esophageal squamous cell carcinomas: Loss of heterozygosity occurs frequently; Loss of imprinting and elevation of p73 expression may be related to defective p53
11. Wild type p73 overexpression and high-grade malignancy in breast cancer
12. P73 gene expression in ovarian cancer tissues and cell lines
13. Elevated and biallelic expression of p73 is associated with progression of human bladder cancer
14. The p73 gene is less involved in the development but involved in the progression of neuroblastoma
15. Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia
16. Expression of p73 and p63 proteins in pancreatic adenocarcinoma: p73 overexpression is inversely correlated with biological aggressiveness
17. Absence of mutation of the p73 gene in astrocytic neoplasms
18. Mutation analysis of the p73 gene in nonastrocytic brain tumours
19. p73 gene transcripts in human brain tumors: Overexpression and altered splicing in ependymomas
20. Increased levels of p21WAF1/Cip1 in human brain tumors
21. Expression of retinoblastoma gene product and p21 (WAF1/Cip 1) protein in gliomas: Correlations with proliferation markers, p53 expression and survival
22. Accumulation of wild-type p53 in astrocytomas is associated with increased p21 expression
23. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations
24. Gene amplification as a prognostic factor in primary brain tumors
25. Amplification and overexpression of mdm2 gene in ependymomas
26. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes
27. MDM2 and p53 expression in gliomas: A multivariate survival analysis including proliferation markers and epidermal growth factor receptor
28. WAF1, a potential mediator of p53 tumor suppression
29. The p53-mdm-2 autoregulatory feedback loop
30. Mdm2 expression is induced by wild type p53 activity
31. Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system
32. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas
33. p53 gene mutations in human astrocytic brain tumors including pilocytic astrocytomas
34. Anaplastic ependymomas: Clinical features and tumour suppressor gene p53 analysis
35. Infrequency of p53 gene mutations in ependymomas
36. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype
37. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases